It's bottoming because of interest rates. Sell it at $65. You can also swap this for Bristol-Myers.
He likes the yield. He believes they are making some headway on a CVT-19 drug on trial in China. They are also doing more M&A to bring innovation into their pipeline. They are working on liver disease drugs and HIV drugs. They have a clean balance sheet as well. Yield 3.68% (Analysts’ price target is $75.22)
Gilead Sciences Inc. is a American stock, trading under the symbol GILD-Q on the NASDAQ (GILD). It is usually referred to as NASDAQ:GILD or GILD-Q
In the last year, 3 stock analysts published opinions about GILD-Q. 2 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Gilead Sciences Inc..
Gilead Sciences Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Gilead Sciences Inc..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
3 stock analysts on Stockchase covered Gilead Sciences Inc. In the last year. It is a trending stock that is worth watching.
On 2022-05-23, Gilead Sciences Inc. (GILD-Q) stock closed at a price of $63.66.